Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children

Not Recruiting

Trial ID: NCT03859700

Age - 2 Years-5 Years Gender - ALL Accepting Healthy Volunteers - No

Purpose

Open-label, follow-up study for subjects who completed the EPITOPE study.

Official Title

EPITOPE Open-label Extension Study to Evaluate the Long-term Clinical Benefit and Safety of DBV712 in Peanut-Allergic Children

Stanford Investigator(s)

Sayantani Sindher

Clinical Associate Professor, Medicine Clinical Associate Professor, Pediatrics - Allergy and Clinical Immunology

Eligibility

Inclusion Criteria:

* completion of the EPITOPE study

Exclusion Criteria:

* Generalized dermatologic disease (for example, active atopic dermatitis, uncontrolled generalized active eczema, ichthyosis vulgaris) extending widely on the skin and especially on the back or arms with no intact zones to apply the Viaskin patches.
* Diagnosis of asthma that evolved to severe, unstable or uncontrolled asthma

View More
View Less

Intervention(s):

biological: DBV712 250 mcg

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305

©2024 Stanford Medicine